SCHEMBL15035951

SCHEMBL15035951

Cc1cc([S+](C)[O-])cnc1C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035944 0.80 KMT2A (0.31)
SCHEMBL15041846 0.76 CYP2A6 (0.35)
SCHEMBL17790320 0.73 UHRF1 (0.33)
SCHEMBL7951929 0.71 NOS3 (0.48)
SCHEMBL16511825 0.70 NOS3 (0.32)
SCHEMBL6124195 0.70 LMNA (0.35)
SCHEMBL19788317 0.68 CYP3A4 (0.34)
SCHEMBL22725617 0.68 NOS3 (0.37)
SCHEMBL2738316 0.68 AGBL2 (0.42)
SCHEMBL20390069 0.68 S1PR3 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912203-B2 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-12-16 US disclosed
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed